[HTML][HTML] Vaccine adjuvants: from 1920 to 2015 and beyond
A Di Pasquale, S Preiss, F Tavares Da Silva, N Garçon - Vaccines, 2015 - mdpi.com
The concept of stimulating the body's immune response is the basis underlying vaccination.
Vaccines act by initiating the innate immune response and activating antigen presenting …
Vaccines act by initiating the innate immune response and activating antigen presenting …
A review of clinical trials of human papillomavirus prophylactic vaccines
JT Schiller, X Castellsagué, SM Garland - Vaccine, 2012 - Elsevier
End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV)
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …
Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition …
LE Markowitz, S Hariri, C Lin, EF Dunne… - The Journal of …, 2013 - academic.oup.com
Background. Human papillomavirus (HPV) vaccination was introduced into the routine
immunization schedule in the United States in late 2006 for females aged 11 or 12 years …
immunization schedule in the United States in late 2006 for females aged 11 or 12 years …
[HTML][HTML] Vaccinations and autoimmune diseases
B Olivieri, C Betterle, G Zanoni - Vaccines, 2021 - mdpi.com
Vaccines represent one of the most effective measures of public health medicine, saving
countless lives and preventing lifelong disabilities. Vaccines are extremely safe, however …
countless lives and preventing lifelong disabilities. Vaccines are extremely safe, however …
Human papillomavirus vaccine introduction–the first five years
LE Markowitz, V Tsu, SL Deeks, H Cubie, SA Wang… - Vaccine, 2012 - Elsevier
The availability of prophylactic human papillomavirus (HPV) vaccines has provided powerful
tools for primary prevention of cervical cancer and other HPV-associated diseases. Since …
tools for primary prevention of cervical cancer and other HPV-associated diseases. Since …
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez… - Bmj, 2012 - bmj.com
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on
the risk of developing subsequent disease after an excisional procedure for cervical …
the risk of developing subsequent disease after an excisional procedure for cervical …
An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015
M Vichnin, P Bonanni, NP Klein… - The Pediatric …, 2015 - journals.lww.com
Background: A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …
[HTML][HTML] Safety of human papillomavirus vaccines: a review
KK Macartney, C Chiu, M Georgousakis… - Drug safety, 2013 - Springer
Vaccination to prevent human papillomavirus (HPV)-related infection leading to cancer,
particularly cervical cancer, is a major public health breakthrough. There are currently two …
particularly cervical cancer, is a major public health breakthrough. There are currently two …
Parents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results
Vaccination against the human papillomavirus (HPV) is an effective primary prevention
measure for HPV-related diseases. For children and young adolescents, the uptake of the …
measure for HPV-related diseases. For children and young adolescents, the uptake of the …
Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
J Gee, C Weinbaum, L Sukumaran… - Human vaccines & …, 2016 - Taylor & Francis
Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United
States in 2006 and through 2015 was the predominate HPV vaccine used. With the …
States in 2006 and through 2015 was the predominate HPV vaccine used. With the …